Utility of hydroxypropylmethylcellulose acetate succinate (HPMCAS) for initiation and maintenance of drug supersaturation in the GI milieu

Pharmaceutical Research

Volumn 26, Issue 6, 2009, Pages 1419-1431

  Curatolo, William ^a   Nightingale, James A ^b   Herbig, Scott M ^a,b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Bend Research Incorporated   (United States)

Author keywords

Bioavailability improvement; Dispersions; HPMCAS; Hydroxypropylmethylcellulose acetate succinate; Low solubility drugs; Spray dried dispersions; Supersaturation

Indexed keywords

2 (4 ETHOXYBENZYL) 1,2 DIHYDROIMIDAZO[1,5 A]QUINOXALIN 3(5H) ONE; 3,6 DIMETHYL 4 (3 PENTOXY) 2 (2,4,6 TRIMETHYLPHENOXY)PYRIDINE; 4B,5,6,7,8,8A,9,10 OCTAHYDRO 7 HYDROXY N [(2 METHYL 3 PYRIDINYL)METHYL] 4B (PHENYLMETHYL) 7 (3,3,3 TRIFLUOROPROPYL) 2 PHENANTHRENECARBOXAMIDE; 5 CHLORO 1H INDOLE 2 CARBOXYLIC ACID [BENZYL 2 (3 HYDROXYAZETIDIN 1 YL) 2 OXOETHYL]AMIDE; 5 CHLORO 1H INDOLE 2 CARBOXYLIC ACID [BENZYLHYDROXY 3 (DIHYDROXYPYRROLIDIN 1 YL) 3 OXOPROPYL]AMIDE; 5 CHLORO N [2 HYDROXY 3 (METHOXYMETHYLAMINO) 3 OXO 1 (PHENYLMETHYL)PROPYL] 1H INDOLE 2 CARBOXAMIDE; EXCIPIENT; GRISEOFULVIN; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; NIFEDIPINE; PHENYTOIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SOLUBILITY; DRUG STRUCTURE; EXCIPIENT COMPATIBILITY; GASTROINTESTINAL TRACT; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; SPRAY DRYING;

CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; GASTROINTESTINAL CONTENTS; HUMANS; METHYLCELLULOSE; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; POWDER DIFFRACTION; PRECIPITATION; SOLUBILITY; TRANSITION TEMPERATURE; X-RAY DIFFRACTION;

EID: 67349139611     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-9852-z     Document Type: Article

References (37)

1. K. Johnson A. Swindell 1996 Guidance in the setting of drug particle size specifications to minimize variability in absorption Pharm. Res. 13 1795 1798 (Pubitemid 27034109)
2. W. Curatolo 1998 Physical chemical properties of oral drug candidates in the discovery and exploratory development settings Pharm. Sci. Tech. Today 1 387 393 (Pubitemid 28559133)
3. C. Lipinski F. Lombardo B. Dominy P. Feeney 1997 Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Del. Reviews 23 3 25 (Pubitemid 27046991)
4. R. Gursoy S. Benita 2004 Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs Biomedicine & Pharmacother. 58 173 182
5. C. W. Pouton 2006 Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system Eur. J. Pharmaceut. Sci. 29 278 287
6. C. J. Porter C. W. Pouton J. F. Cuine W. N. Charman 2008 Enhancing intestinal drug solubilization using lipid-based delivery systems Adv. Drug Del. Rev. 60 673 691
7. C. W. Pouton C. J. Porter 2008 Formulation of lipid-based delivery systems for oral administration: Materials, methods, and strategies Adv. Drug Del. Rev. 60 625 637
8. K. Sekiguchi N. Obi 1961 Studies on absorption of eutectic mixtures. I. A comparison of the behavior of eutectic mixtures of sulphathiazole and that of ordinary sulphathiazole in man Clin. Pharm. Bull. 9 866 872
9. A. H. Goldberg M. Gibaldi J. L. Kanig 1965 Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures I-theoretical considerations and discussions of the literature J. Pharm. Sci. 54 1145 1148
10. A. H. Goldberg M. Gibaldi J. L. Kanig 1966 Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures II-experimental evaluation of a eutectic mixture: urea-acetaminophen system J. Pharm. Sci. 55 482 487
11. R. T. Stoll T. R. Bates K. A. Nieforth J. Swarbrick 1969 Some physical factors affecting the enhanced blepharoptotic activity of orally administered reserpine-cholanic acid coprecipitates J. Pharm. Sci. 58 1457 1459
12. R. Stoll T. Bates J. Swarbrick 1973 In vitro dissolution and in vivo absorption of nitrofurantoin from deoxycholic acid coprecipitates J. Pharm. Sci. 62 65 68
13. W. L. Chiou S. Riegelman 1969 Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin J. Pharm. Sci. 58 1505 1510 (Pubitemid 11032849)
14. W. L. Chiou S. Riegelman 1971 Pharmaceutical applications of solid dispersion systems J. Pharm. Sci. 60 1281 1302
15. A. P. Simonelli S. C. Mehta W. I. Higuchi 1976 Dissolution rates of high energy sulfathiazole-povidone coprecipitates II-characterization of form of drug controlling its dissolution rate via solubility studies J. Pharm. Sci. 65 355 361
16. T. Higuchi R. Kuramoto 1954 Study of possible complex formation between macromolecules and certain pharmaceuticals J. Amer. Pharm. Assn. XLIII 393 397
17. D. Horn W. Ditter 1982 Chromatographic study of interactions between polyvinylpyrrolidone and drugs J. Pharm. Sci. 71 1021 1026 (Pubitemid 12064225)
18. W. L. Chiou S. Riegelman 1970 Oral absorption of griseofulvin in dogs: Increased absorption via solid dispersion in polyethyleneglycol 6000 J. Pharm. Sci. 59 937 942
19. A. Serajuddin 1999 Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs J. Pharm. Sci. 88 1058 1066 (Pubitemid 29480600)
20. C. Leuner J. Dressman 2000 Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharmaceutics Biopharmaceutics 50 47 60 (Pubitemid 30326688)
21. W. Curatolo, S. Herbig, and J. A. S. Nightingale. Solid pharmaceutical dispersions with enhanced bioavailability. European Patent EP-0901786B1, published March 17, 1999; granted June 13, 2007 (1999).
22. M. Crew, D. Friesen, B. Hancock, C. Macri, J. A. S. Nightingale, and R. M. Shanker. Pharmaceutical compositions of a sparingly soluble glycogen phosphorylase inhibitor. US Patent 7,235,260B2; International Patent WO-01/68092A2 Publication Date Sept. 20, 2001 (2001).
23. R. Beyerinck, H. Deibele, D. Dobry, R. Ray, D. Settell, and K. Spence. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus. US Patent Application 2003/0163931A1, published Sept. 4, 2003 (2003).
24. R. Beyerinck, D. Dobry, D. Friesen, D. Settell, and R. Ray. Spray drying processes for forming solid amorphous dispersions of drugs and polymers. US Patent Application 2005/0031692A1, published Feb. 10, 2005 (2005).
25. D. Friesen R. Shanker M. Crew D. Smithey W. Curatolo J. A. S. Nightingale 2008 Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: An overview Molec. Pharmaceut. 5 1003 1009
26. M. Gordon J. S. Taylor 1952 Ideal co-polymers and the second order transitions of synthetic rubbers. 1. Non-crystalline copolymers J. Appl. Chem. 2 493 500
27. W. C. Babcock, D. Friesen, J. A. S. Nightingale, and R. Shanker. Pharmaceutical solid dispersions. European Patent Application EP-1027886A2, published Aug. 16, 2000 (2000).
28. A. Dokoumetzidis P. Macheras 2006 A century of dissolution research: from Noyes and Whitney to the Biopharmaceutics Classification System International J. Pharmaceut. 321 1 11 (Pubitemid 44247428)
29. D. Horter J. B. Dressman 2001 Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract Adv. Drug Del. Rev. 46 75 87
30. E. Nicolaides M. Symillides J. B. Dressman C. Reppas 2001 Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration Pharm. Res. 18 380 388 (Pubitemid 32595828)
31. M. Carey D. Small C. Bliss 1983 Lipid digestion and absorption Ann. Rev. Physiol. 45 651 677 (Pubitemid 15162730)
32. O. Hernell J. E. Staggers M.C. Carey 1990 Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings Biochemistry 29 2041 2056 (Pubitemid 20085429)
33. W. Admirand D. M. Small 1968 The physicochemical basis of cholesterol gallstone formation in man J. Clin. Invest. 47 1043 1052
34. J. Sjovall 1960 Bile acids in man under normal and pathological conditions Clin. Chem. Acta 5 33 41
35. T. Northfield I. McColl 1973 Postprandial concentrations of free and conjugated bile acids down the length of the normal human small intestine Gut 14 513 518
36. W. C. Babcock, M. Crew, D. Friesen, M. Rabenstein, D. Smithey, and R. Shanker. Pharmaceutical compositions containing polymer and drug assemblies. European Patent Application WO-03/000226A2, published Jan. 3, 2003 (2003).
37. E. Jantratid N. Janssen C. Reppas J. B. Dressman 2008 Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update Pharm. Res. 25 1663 1676